Allarity Therapeutics (ALLR) Announces Final Settlement with the U.S. Securities and Exchange Commission Mar 13, 2025 08:33AM
Allarity Therapeutics Announces Final Settlement with the U.S. Securities and Exchange Commission Mar 13, 2025 08:30AM
Allarity Therapeutics (ALLR) Announces Board Authorization of $5 Million Share Repurchase Program Mar 3, 2025 08:01AM
Allarity Therapeutics Announces Board Authorization of $5 Million Share Repurchase Program Mar 3, 2025 08:00AM
Allarity Therapeutics Announces Dismissal of Securities Class Action Lawsuit Feb 26, 2025 08:00AM
View Older Stories

Feb 24, 2025 08:00AM Allarity Therapeutics to Begin Enrollment for New Phase 2 Protocol to Advance Stenoparib Toward FDA Approval in Advanced Ovarian Cancer Patients
Feb 6, 2025 08:01AM Allarity Therapeutics (ALLR) Announces Expansion of Phase 2 Clinical Trial to Accelerate Development of Stenoparib in Advanced Ovarian Cancer
Feb 6, 2025 08:00AM Allarity Therapeutics Announces Expansion of Phase 2 Clinical Trial to Accelerate Development of Stenoparib in Advanced Ovarian Cancer
Jan 30, 2025 08:06AM Allarity Therapeutics (ALLR) Announces Filing of Form 8-K Regarding Settlement Agreement in Principle with SEC
Jan 30, 2025 08:00AM Allarity Therapeutics Announces Filing of Form 8-K Regarding Settlement Agreement in Principle with SEC
Nov 18, 2024 08:03AM Allarity Therapeutics (ALLR) Reports Key Progress in Phase 2 Stenoparib Trial
Nov 18, 2024 08:00AM Allarity Therapeutics Reports Key Progress in Phase 2 Stenoparib Trial and Strategic Corporate Advancements
Nov 14, 2024 08:00AM Allarity Therapeutics Reports Third Quarter 2024 Financial Results and Provides Recent Operational Highlights
Oct 22, 2024 08:00AM Allarity Therapeutics (ALLR) to be Granted European Patent for DRP® Companion Diagnostic for Stenoparib
Oct 22, 2024 08:00AM Allarity Therapeutics to be Granted European Patent for DRP® Companion Diagnostic for Stenoparib
Oct 10, 2024 08:00AM Allarity Therapeutics (ALLR) Regains Compliance with NASDAQ Minimum Bid Price Requirement
Oct 10, 2024 08:00AM Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Requirement
Oct 3, 2024 08:00AM Allarity Therapeutics Strengthens Leadership with Key Appointments to Accelerate Stenoparib PARP Inhibitor Program
Sep 16, 2024 08:00AM Allarity Therapeutics (ALLR) Announces Two Patients Now Exceeding One Year of Treatment with Stenoparib in Advanced Ovarian Cancer Trial
Sep 16, 2024 08:00AM Allarity Therapeutics Announces Two Patients Now Exceeding One Year of Treatment with Stenoparib in Advanced Ovarian Cancer Trial
Sep 13, 2024 08:46AM Allarity Therapeutics (ALLR) Announces New CFO and Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sep 13, 2024 08:45AM Allarity Therapeutics Announces New CFO and Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Sep 11, 2024 08:00AM Allarity Therapeutics (ALLR) Announces 1:30 Reverse Share Split
Sep 11, 2024 08:00AM Allarity Therapeutics Takes Decisive Step Toward Regaining Nasdaq Compliance with Nasdaq Listing Rule 5550(a)(2)
Jul 26, 2024 09:00AM Allarity Therapeutics Announces Postponement of Annual Stockholders Meeting
Jul 24, 2024 06:02AM Allarity Therapeutics (ALLR) Encourages Shareholders to Vote FOR the Reverse Stock Split
Jul 24, 2024 06:00AM Allarity Encourages Shareholders to Vote FOR the Reverse Stock Split and Decrease in Authorized Shares
Jul 22, 2024 06:32AM Allarity Therapeutics (ALLR) Outlines Company’s 2024 Progress and Objectives
Jul 22, 2024 06:30AM Allarity Therapeutics Outlines Company’s 2024 Progress and Objectives
Jun 27, 2024 08:01AM Allarity Therapeutics (ALLR) Granted Hearing to Regain Nasdaq Compliance
Jun 27, 2024 08:00AM Allarity Granted Hearing Before Nasdaq Panel to Present Plan of Regaining Compliance
Jun 25, 2024 08:00AM Allarity Therapeutics’ Dual PARP/Tankyrase Inhibitor, Stenoparib, Continues to Show Extended Clinical Benefit in Advanced Ovarian Cancer
May 20, 2024 08:02AM Allarity Therapeutics (ALLR) Regains Nasdaq Compliance
May 20, 2024 08:00AM Allarity Therapeutics (ALLR) Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement
May 20, 2024 08:00AM Allarity Therapeutics Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement
May 20, 2024 08:00AM Allarity Therapeutics Regains Compliance with Nasdaq's Minimum Stockholders' Equity Requirement
May 14, 2024 04:01PM Allarity Therapeutics Reports First Quarter Financial Results and Highlights, including Clear Clinical Benefits from Phase 2 Trial, NASDAQ Compliance, and Significant Improvement in Cash and Equity Ba
May 7, 2024 09:30AM Allarity Therapeutics Announces that All Series A Preferred and All Variable Priced Warrants have Converted to Common Stock
May 6, 2024 08:00AM Allarity Therapeutics Exceeds Nasdaq’s Minimum Equity Requirement; Requests Voluntarily Withdrawal of Form S-1
May 2, 2024 08:03AM Allarity Therapeutics' (ALLR) Stenoparib Shows Clear Clinical Benefit and Achieves Significant Milestone in Phase 2
May 2, 2024 08:00AM Allarity Therapeutics’ Stenoparib Shows Clear Clinical Benefit and Achieves Significant Milestone with Early Conclusion of Phase 2 Trial in Advanced Ovarian Cancer
Apr 29, 2024 07:02AM Allarity Therapeutics (ALLR) Regains Nasdaq Compliance
Apr 29, 2024 07:00AM Allarity Therapeutics Regains Compliance with NASDAQ Minimum Bid Price Requirement
Apr 17, 2024 09:10AM Allarity Therapeutics (ALLR) Granted Nasdaq Extension to Regain Compliance
Apr 17, 2024 09:10AM Allarity Therapeutics Receives NASDAQ-Approved Extension to Regain Compliance with Nasdaq Listing Rule 5550(b)(1)
Apr 4, 2024 09:15AM Allarity Therapeutics (ALLR) Announces 1:20 Reverse Share Split
Apr 4, 2024 09:15AM Allarity Therapeutics Announces 1-for-20 Reverse Stock Split
Mar 27, 2024 08:32AM Allarity Therapeutics (ALLR) to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval
Mar 27, 2024 08:30AM Allarity Therapeutics Makes Strategic Pivot to Focus Solely on Accelerating Stenoparib Toward Regulatory Approval in Advanced Recurrent Ovarian Cancer
Mar 25, 2024 07:32AM Allarity Therapeutics (ALLR) Receives Nasdaq Extension to Regain Compliance
Mar 25, 2024 07:30AM Allarity Therapeutics Receives Extension from Nasdaq Hearings Panel to Regain Compliance with Listing Rules 5550(a)(2) and 5550(b)(1)
Mar 8, 2024 07:15AM Allarity Therapeutics Reports Full Year 2023 Financial Results and Provides a Business Update
Feb 28, 2024 06:00AM Allarity Therapeutics to Present at Biomarkers 2024
Dec 12, 2023 06:00AM Allarity Therapeutics (ALLR) Appoints Thomas Jensen as Interim CEO
Dec 12, 2023 06:00AM Allarity Therapeutics Announces Thomas Jensen as Interim CEO and Appointment of Jeremy R. Graff, PhD as Key Executive Advisor
View Older Stories